Page 3 - Dr Reddys Laboratories Ltd News

Sensex drops 500 pts, Nifty below 25,200 as IT stocks drag

Even broader markets failed to trade in the green territory. The Nifty midcap 100 was trading at 58,954.15, down by 0.60 per cent.

How to trade Dr Reddys, Tata Consumer, Bajaj Housing post Q1 results?

Technical charts hint at a likely positive bias for Dr Reddy's stock, while a negative outlook for Tata Consumer. Bajaj Housing Finance is likely to remain range-bound.

Dr Reddy's Laboratories Q1 print misses target; brokerages split on outlook

Dr Reddy's Laboratories' posted a revenue of ₹8,545.2 crore, up 11 per cent year-on-year (Y-o-Y) but flat sequentially.

Stocks to Watch today, July 24: Infosys, Dr Reddy's, Coforge, Tata Consumer

Stocks to Watch today, July 24, 2025: Infosys, IndusInd Bank, BEML and Bajaj Housing Finance are some of the top stocks to watch today.

Dr Reddy Laboratories Q1 profit up 2%, posts best ever quarterly revenue

Dr Reddy's reported Rs 1,417 crore net profit in Q1 FY26, driven by new launches and price hikes; firm outlines global semaglutide strategy and GLP-1 product pipeline

Dr Reddy's to launch obesity drug in 87 nations starting next year: CEO

The company initially plans to launch the generic version in Canada, India, Brazil, Turkey and other emerging markets, subject to patent expiry, Israeli said at a press conference

Dr Reddy's Q1 profit up 1% to ₹1,410 crore, revenue rises to ₹8,545 cr

Dr Reddy's Laboratories on Wednesday reported a 1 per cent increase in consolidated net profit to Rs 1,410 crore during the Juen quarter. The Hyderabad-based drug major reported a net profit of Rs 1,392 crore in the year-ago period. Revenue increased to Rs 8,545 crore in he period under review from Rs 7,673 crore a year earlier. "We delivered double-digit growth this quarter over the same period last year, reflecting our strength in branded markets and positive momentum in the Nicotine Replacement Therapy portfolio," Dr Reddy's Co-Chairman & MD G V Prasad said. The pricing pressure on Lenalidomide is expected to intensify in the US generics market, he noted. "We remain focused on strengthening our base business by delivery of our pipeline assets, improving overall productivity and business development," Prasad said. Shares of the company ended 0.58 per cent up at Rs 1,247.55 apiece on the BSE.

Here's what brokerages expect from Dr Reddy's Labs ahead of Q1 show

Dr Reddy's Labs Q1 preview: The company's net profit is expected to come at ₹1,460 crore, marking around 4.9 per cent Y-o-Y increase, on average, as against ₹1,392.4 crore in Q1 FY25

Stock to Watch today, July 21: Reliance, HDFC Bank, ICICI Bank, Dr. Reddy's

Stocks to Watch today, July 21, 2025: Reliance, HDFC Bank, Yes Bank and JSW Steel are some of the key stocks to watch today

Dr Reddy's gets 7 USFDA observations after Srikakulam plant inspection

A Form 483 is issued by the US health regulator when inspectors identify conditions that may violate the Food, Drug, and Cosmetic (FD&C) Act or relevant guidelines

Dividend stocks: These 4 stocks to go ex-date on July 10; are you eligible?

The ex-dividend date signifies the day from which a stock trades without the entitlement to the declared dividend. Thus, the investors must hold the shares prior to this date to qualify

Dr Reddy's expects US sales dip in FY26, aims for resilience via scale-up

With increased US competition from FY26, DRL plans portfolio shifts, inorganic growth, cost control and global expansion to manage profit and revenue impact